Detecting oral and throat cancers using a saliva test

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the safety and efficacy of the OralViome Cancer Testing system for early detection of oral and throat cancers through saliva metatranscriptomic analysis. A total of 475 participants will be recruited from various clinical sites, including cancer-free individuals, those with Oral Potentially Malignant Disease (OPMD), and patients diagnosed with Oral Squamous Cell Carcinoma (OSCC) or OroPharyngeal Cancer (OPC). Participants will complete health questionnaires and provide saliva samples using kits supplied by Viome, with study participation lasting up to one year for certain cohorts.

Why it matters

Who can join: the full rules

Inclusion Criteria

* Signed Informed Consent obtained
* 18 years and older
* At a high risk of developing oral or throat cancer based on clinician's discretion

Exclusion Criteria

* Pregnancy
* Use of fertility enhancing medications

Where it's running

• Nymc
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Cristina Julian, PhD — Viome
• Study coordinator: Mory Mehrtash, MSc
• Email: studies@viome.com
• Phone: 425-300-6933

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sacituzumab govitecan plus cetuximab for recurrent or metastatic head and neck squamous cell cancer

  This trial will test whether combining sacituzumab govitecan with cetuximab works and is safe for people whose head and neck squamous cell cancer has returned or spread after prior immunotherapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07063212

• Salivary IL-8 and Serum IL-6 as Biomarkers to Distinguish Oral Premalignant Disorders in Smokers and Never-Smokers

  This study tests whether salivary IL-8 and blood IL-6 can help tell apart adults with oral premalignant conditions from those with healthy mouths, and whether smoking influences these markers.

  Recruiting British University In Egypt · Cairo · NCT07915570

• Docetaxel and SX-682 in head and neck cancers and prostate cancer

  This trial tests a new drug SX-682 together with docetaxel in adults whose head and neck cancers or prostate cancer have returned or spread.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07667400

• Patient-specific 3D-printed titanium implants for facial reconstruction

  This study tests whether custom-made 3D-printed titanium facial implants can improve reconstruction and appearance for adults with facial bone defects or asymmetry.

  Recruiting Latakia University · Latakia · NCT07654647

• Comparing dual-energy CT and MRI for staging oral and oropharyngeal squamous cell carcinoma

  This will test whether 40 keV dual-energy CT can replace a contrast-enhanced neck and facial MRI for staging adults with oral or oropharyngeal squamous cell carcinoma.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07343271

• Adaptive compression anastomosis for anterior resection in sigmoid and upper rectal cancer or premalignant lesions

  This study will test a removable silicone compression ring (C-REX RectoAid Cath) to create the bowel connection during elective anterior resection for people with sigmoid or proximal rectal cancer or premalignant lesions.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam · NCT07056374

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.